Show simple item record

dc.contributor.authorPatel, Aen_US
dc.contributor.authorMcCrone, Pen_US
dc.contributor.authorLeese, Men_US
dc.contributor.authorAmaddeo, Fen_US
dc.contributor.authorTansella, Men_US
dc.contributor.authorKilian, Ren_US
dc.contributor.authorAngermeyer, Men_US
dc.contributor.authorKikkert, Men_US
dc.contributor.authorSchene, Aen_US
dc.contributor.authorKnapp, Men_US
dc.date.accessioned2016-11-14T15:14:59Z
dc.date.available2013-05-15en_US
dc.date.issued2013-05-25en_US
dc.date.submitted2016-09-20T09:00:29.863Z
dc.identifier.issn1478-7547en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/17637
dc.description.abstractBACKGROUND: Non-adherence to anti-psychotics is common, expensive and affects recovery. We therefore examine the cost-effectiveness of adherence therapy for people with schizophrenia by multi-centre randomised trial in Amsterdam, London, Leipzig and Verona. METHODS: Participants received 8 sessions of adherence therapy or health education. We measured lost productivity and use of health/social care, criminal justice system and informal care at baseline and one year to estimate and compare mean total costs from health/social care and societal perspectives. Outcomes were the Short Form 36 (SF-36) mental component score (MCS) and quality-adjusted life years (QALYs) gained (SF-36 and EuroQoL 5 dimension (EQ5D)). Cost-effectiveness was examined for all cost and outcome combinations using cost-effectiveness acceptability curves (CEACs). RESULTS: 409 participants were recruited. There were no cost or outcome differences between adherence therapy and health education. The probability of adherence therapy being cost-effective compared to health education was between 0.3 and 0.6 for the six cost-outcome combinations at the willingness to pay thresholds we examined. CONCLUSIONS: Adherence therapy appears equivalent to health education. It is unclear whether it would have performed differently against a treatment as usual control, whether such an intervention can impact on quality of life in the short-term, or whether it is likely to be cost-effective in some sites but not others. TRIAL REGISTRATION: Trial registration: Current Controlled Trials ISRCTN01816159.en_US
dc.description.sponsorshipQuality of Life and Management of Living Resources Programme of the European Union (grant number QLG4-CT-2001-01734)en_US
dc.format.extent12 - ?en_US
dc.languageengen_US
dc.relation.ispartofCost Eff Resour Allocen_US
dc.rightsThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.titleCost-effectiveness of adherence therapy versus health education for people with schizophrenia: randomised controlled trial in four European countries.en_US
dc.typeArticle
dc.rights.holdern is available at the end of the article (c) 2013 Patel et al.; licensee BioMed Central Ltd.
dc.identifier.doi10.1186/1478-7547-11-12en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/23705862en_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.publication-statusPublished onlineen_US
pubs.volume11en_US
dcterms.dateAccepted2013-05-15en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record